These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21169853

  • 1. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids.
    Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F.
    J Clin Rheumatol; 2011 Jan; 17(1):23-7. PubMed ID: 21169853
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A case of macrophage activation syndrome successfully treated with anakinra.
    Kelly A, Ramanan AV.
    Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
    [Abstract] [Full Text] [Related]

  • 4. Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis.
    Nádia EA, Carvalho JF, Bonfá E, Lotito AP, Silva CA.
    Isr Med Assoc J; 2009 Oct; 11(10):635-6. PubMed ID: 20077954
    [No Abstract] [Full Text] [Related]

  • 5. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
    Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, Zuiderveen S, Birmingham J.
    Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [Abstract] [Full Text] [Related]

  • 7. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
    Verbsky JW, White AJ.
    J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
    [Abstract] [Full Text] [Related]

  • 8. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC.
    Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
    [Abstract] [Full Text] [Related]

  • 9. The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm.
    Szyper-Kravitz M.
    Isr Med Assoc J; 2009 Oct; 11(10):633-4. PubMed ID: 20077953
    [No Abstract] [Full Text] [Related]

  • 10. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.
    Kahn PJ, Cron RQ.
    J Rheumatol; 2013 May; 40(5):743-4. PubMed ID: 23637382
    [No Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
    Swart JF, Barug D, Möhlmann M, Wulffraat NM.
    Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
    [Abstract] [Full Text] [Related]

  • 12. Macrophage activation syndrome treated with anakinra.
    Durand M, Troyanov Y, Laflamme P, Gregoire G.
    J Rheumatol; 2010 Apr; 37(4):879-80. PubMed ID: 20360206
    [No Abstract] [Full Text] [Related]

  • 13. Intravenous administration of anakinra in children with macrophage activation syndrome.
    Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S.
    Pediatr Rheumatol Online J; 2021 Jun 29; 19(1):98. PubMed ID: 34187503
    [Abstract] [Full Text] [Related]

  • 14. [Macrophage activation syndrome and systemic onset of juvenile idiopathic arthritis].
    Iglesias Jiménez E, Camacho Lovillo MS, Lirola Cruz MJ, Falcón Neyra D, Neth O.
    An Pediatr (Barc); 2010 Mar 29; 72(3):230-1. PubMed ID: 20097627
    [No Abstract] [Full Text] [Related]

  • 15. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov 29; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

  • 16. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G.
    Arthritis Rheum; 2003 Apr 29; 48(4):927-34. PubMed ID: 12687534
    [Abstract] [Full Text] [Related]

  • 17. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B.
    Ann Rheum Dis; 2006 Aug 29; 65(8):1006-12. PubMed ID: 16396977
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
    Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P.
    Arthritis Rheum; 2010 Jan 29; 62(1):258-67. PubMed ID: 20039428
    [Abstract] [Full Text] [Related]

  • 19. Recognition and management of macrophage activation syndrome in juvenile arthritis.
    Kelly A, Ramanan AV.
    Curr Opin Rheumatol; 2007 Sep 29; 19(5):477-81. PubMed ID: 17762614
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.
    Loh NK, Lucas M, Fernandez S, Prentice D.
    Intern Med J; 2012 Dec 29; 42(12):1358-62. PubMed ID: 23253002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.